This template was built with Webflow's free Prospero UI Kit. Learn more
If you are reading this, you have probably just typed one of the hardest questions a parent can ask into a search engine. You want to know what an SCN2A diagnosis means for your child’s future — and specifically, how long your child might live. That question deserves an honest answer. Here is the truth: there is no reliable average life expectancy figure specific to SCN2A-related disorders as a whole. But the absence of a single number does not mean the absence of knowledge. Researchers and clinicians understand more about SCN2A outcomes today than at any point in history, and that understanding is growing rapidly.
SCN2A is a gene that provides instructions for making a sodium channel protein critical to brain development and function. Variants in this gene cause a wide spectrum of conditions, from seizures that resolve on their own in infancy, to severe developmental and epileptic encephalopathies (DEEs), which are conditions where developmental impairment arises from both the underlying genetic cause and the effects of epileptic activity itself. Published research describes a broad and overlapping spectrum of clinical presentations associated with SCN2A variants. These include self-limited neonatal or infantile seizures, neurodevelopmental and neuropsychiatric conditions including intellectual disability and autism, infantile epileptic spasms syndrome, early-onset DEEs, and episodic ataxia.
Many individuals show features that span more than one category, and presentations can evolve over time. A computational analysis of more than 10,860 phenotypic annotations across 413 individuals with SCN2A-related disorders underscores just how broad and varied this clinical spectrum is. This range is the core reason why a single life expectancy figure does not exist. A person with a mild, inherited SCN2A variant and a person with a severe, spontaneous (de novo) variant often have very different health trajectories — though variant type alone does not predict outcome.
Grouping all individuals into one statistic would be misleading and potentially harmful. SCN2A was first associated with epilepsy over two decades ago, with initial reports published in 2001–2002. However, the recognition of the full phenotypic spectrum, particularly severe de novo presentations, has expanded significantly only in the past ten to fifteen years. The large, long-term studies needed to generate population-level survival data, studies that track hundreds or thousands of individuals over decades, are only now getting underway. Until those studies mature, we must look at what the existing evidence does tell us.
While no reliable cohort-wide life expectancy figure has been established, published research does describe a range of outcomes based on variant type and clinical presentation.
Some individuals with SCN2A variants experience self-limited neonatal-infantile epilepsy (historically called benign familial neonatal-infantile seizures, or BFNIS) — seizures that typically appear within the first months of life and often resolve spontaneously by early childhood. Many of these individuals go on to have typical development. Inherited SCN2A variants are often associated with milder phenotypes, though this is a pattern rather than a rule. These inherited variants, often gain-of-function (GOF) missense changes passed from a parent, are generally linked to milder presentations. For many families in this group, long-term health expectations are encouraging, but individual outcomes still vary. It is worth noting that “self-limited” does not always mean “no lasting impact.” Some children in this group may still experience learning differences or mild developmental delays. But the overall trajectory for inherited, milder variants tends to be positive, with seizures often resolving and development continuing to progress.
At the more severe end of the spectrum, de novo GOF variants can cause developmental and epileptic encephalopathies (DEEs) such as early infantile DEE (historically called Ohtahara syndrome) or infantile epileptic spasms syndrome (historically called West syndrome). DEE describes conditions where developmental impairment arises from both the underlying genetic cause and the effects of epileptic activity itself. These conditions typically present with seizures within the first three months of life and are associated with significant developmental challenges. Loss-of-function (LOF) variants, where the SCN2A protein has reduced activity, are more often associated with autism spectrum disorder (ASD), intellectual disability, and later-onset or absent seizures. These variants include truncating, splice-site, and some missense changes. Many truncating variants produce little functional protein through a cellular quality-control process called nonsense-mediated decay, rather than producing a stable shortened channel. Outcomes in this group vary widely depending on the degree of developmental involvement and the specific supports available to each individual.
It is important to understand that the genetic change itself does not worsen over time, and SCN2A disorders are not considered neurodegenerative in the way that some progressive neurological conditions are, based on current understanding. However, the clinical picture can evolve as a child grows, seizure types may change, movement difficulties can emerge, and some children may experience developmental stagnation or regression, particularly during periods of frequent seizure activity. This is a meaningful distinction for families trying to understand what the future holds.
Because SCN2A outcomes vary so widely, several factors play a meaningful role in shaping each individual’s long-term health.
For individuals who experience seizures, how well those seizures are managed is one of the most significant factors influencing overall health and quality of life. Frequent generalized tonic-clonic seizures (GTCS), a type involving loss of consciousness and full-body convulsions, are the strongest established risk factor for serious seizure-related complications, including the risk of injury and the risk of sudden unexpected death in epilepsy (SUDEP).
Treatment for SCN2A should be individualized based on each person’s specific variant, clinical presentation, and response to therapy, not on GOF or LOF classification alone. This distinction matters because medications that help one variant type may be ineffective or even harmful for another. Recent research has shown that the mechanisms of SCN2A loss of function do not reliably predict the presence or type of epilepsy, reinforcing the need for personalized treatment strategies. Getting the right treatment early, and avoiding the wrong one, can improve seizure control, which may in turn support development, though developmental outcomes are also shaped by the underlying genetic cause itself. Working with a neurologist experienced in genetic epilepsies, ideally guided by current SCN2A research, is essential. Long-term follow-up is also critical, as the neurological and developmental needs of individuals with SCN2A may shift across different stages of life.
Early intervention services, speech and occupational therapy, behavioral support, and educational accommodations can meaningfully improve quality of life, skill development, and participation for children with developmental differences related to SCN2A. These supports do not change the underlying genetics, but they help each child build skills and reach their fullest potential.
SUDEP — sudden unexpected death in epilepsy — is a concern for all families managing epilepsy, and it deserves transparent discussion. SUDEP is estimated to account for approximately 3,000 deaths annually in the United States across all forms of epilepsy. No reliable population-wide SUDEP rate specific to SCN2A has been established, and it is not possible to directly apply rates from other epilepsy syndromes. However, SUDEP has been reported in individuals with SCN2A-related genetic developmental and epileptic encephalopathies. A 2023 study by Donnan et al. documented rates of SUDEP and status epilepticus across several genetic DEEs, confirming that SCN2A-associated SUDEP does occur — though the cohort was relatively small and the findings should be interpreted with that limitation in mind.
According to the AAN and AES practice guideline on SUDEP, the overall incidence of SUDEP in epilepsy is approximately 1 in 4,500 children per year and 1 in 1,000 adults per year. For individuals experiencing three or more generalized tonic-clonic seizures per year, the risk rises substantially. The strongest established risk factors include frequent generalized tonic-clonic seizures, particularly nocturnal generalized tonic-clonic seizures, and uncontrolled seizure burden. Families should discuss seizure management and optimization strategies, nighttime monitoring options, and seizure action plans with their care team, keeping in mind that no monitoring device has been proven to prevent SUDEP. SUDEP is not the only serious health risk for individuals with severe SCN2A-related disorders.
Status epilepticus, prolonged seizures that do not stop on their own, respiratory infections, aspiration related to feeding and swallowing difficulties, and complications of prolonged immobility can all affect long-term health and survival. These risks are not unique to SCN2A but are important for families managing any severe epilepsy syndrome to discuss with their medical team.
The reason no reliable life expectancy figure has been established for SCN2A is not because the question is unanswerable, it is because the studies needed to answer it are still maturing. Several major initiatives are working to close this gap.
The Dragonfly Study is a longitudinal natural history registry tracking individuals with SCN2A-related disorders over time through the IAMRARE platform. Studies like this one are designed to capture exactly the kind of long-term outcome data that families are searching for. The Simons Searchlight SCN2A research program is another important initiative collecting genetic, medical, and behavioral data from families to deepen scientific understanding of the condition.
The SCN2A WorldMap, a privacy-first global registry built by the SCN2A Foundation, serves a different but complementary role. It creates a consented, geolocated cohort that makes the SCN2A community visible to pharmaceutical companies, regulators, and research funders, and connects families who share identical variants across the globe. The WorldMap supports cohort visibility and the therapeutic-development pipeline, while initiatives like the Dragonfly Study and Simons Searchlight are the programs designed to collect the longitudinal clinical data that will directly inform questions about long-term prognosis.
Active research into gene therapy, antisense oligonucleotide (ASO) therapies, treatments that target the genetic instructions themselves, and mutation-specific drug development is advancing steadily. These approaches aim not just to manage symptoms but to address the root cause of SCN2A-related disorders. One SCN2A ASO therapy, Elsunersen, is currently in a Phase 3 clinical trial (EMBRAVE3, NCT07019922) for early-onset SCN2A-related DEE. The trial was initially designed as a randomized, double-blind, sham-controlled study but was subsequently converted, with FDA agreement, to a single-arm, baseline-controlled design in which all enrolled patients receive elsunersen for 24 weeks, followed by a treatment extension.
Separately, in June 2026, Elsunersen received FDA Breakthrough Therapy Designation, specifically for the treatment of seizures associated with SCN2A-DEE caused by gain-of-function variants, which provides expedited development and more intensive FDA guidance for drugs that treat serious conditions with preliminary evidence of substantial improvement over existing therapies. This designation does not currently extend to loss-of-function variants. Kim-McManus et al. have also published individualized ASO treatments for SCN2A-related DEE in Nature Medicine, first reporting on a preterm infant in 2025, and then on two patients ages 9 and 14 in 2026, landmark examples of precision medicine tailored to each patient’s specific variant.
While no gene-modifying therapy is currently approved for clinical use, the pipeline is active and growing. The pace of discovery in genetic epilepsy has accelerated dramatically in recent years, and SCN2A is increasingly recognized as a priority target. Every new study, every family enrolled in a registry, and every dollar invested in precision medicine brings the field closer to therapies that could fundamentally change the outlook for individuals living with SCN2A-related disorders.
While the research community works toward better data and new therapies, families can take meaningful action right now: Build your care team. Connect with a neurologist and geneticist experienced in SCN2A and sodium channel disorders. Know your child’s variant type, if known. Understanding whether your child’s variant is GOF, LOF, or mixed function — when this information is available — helps guide treatment decisions. Not all variants have been functionally characterized, and your geneticist or neurologist can help clarify what is known about your child’s specific variant. Participate in research. Enrolling in the Dragonfly Study or Simons Searchlight contributes to the longitudinal clinical data that will inform long-term outcome questions. Registering on the SCN2A WorldMap helps make the community visible to researchers and industry. You can join families and researchers working to accelerate this progress. Discuss SUDEP risk. Talk with your child’s care team about seizure optimization strategies, nighttime monitoring options, and seizure action plans. Pursue early intervention. Developmental therapies and educational support make a real difference in quality of life and skill development.
Every family navigating an SCN2A diagnosis deserves answers, community, and hope. The work to find them depends on your support. Please consider making a donation to help fund the research and resources that move us all forward.
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
SCN2A Foundation. “Understanding an SCN2A Prognosis: What Families Need to Know.” https://www.scn2afoundation.org/post/understanding-an-scn2a-prognosis-what-families-need-to-know
Wolff, M., et al. (2017). “Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders.” Brain, 140(5), 1316–1336. https://academic.oup.com/brain/article/140/5/1316/3098477
Wolff, M., Brunklaus, A., & Zuberi, S.M. (2019). “Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond.” Epilepsia. https://onlinelibrary.wiley.com/doi/abs/10.1111/epi.14935
Berg, A.T., et al. (2024). “Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders.” Brain, 147(8), 2761. https://academic.oup.com/brain/article/147/8/2761/7656659
Goad, B.S., et al. (2025). “Development and Adaptive Function in Individuals With SCN2A-Related Disorders.” Neurology, 105(3). https://www.neurology.org/doi/10.1212/WNL.0000000000213868
Tan, M., et al. (2026). “Mechanisms of SCN2A loss of function do not predict presence or phenotype of epilepsy.” Epilepsia. https://onlinelibrary.wiley.com/doi/10.1002/epi.70100
Crawford, K., et al. (2021). “Computational Analysis of 10,860 Phenotypic Annotations in Individuals with SCN2A-Related Disorders.” Genetics in Medicine, 23(10), 1940–1950. https://www.nature.com/articles/s41436-021-01120-1
Donnan, A.M., et al. (2023). “Rates of Status Epilepticus and Sudden Unexplained Death in Epilepsy in People With Genetic Developmental and Epileptic Encephalopathies.” Neurology. https://pmc.ncbi.nlm.nih.gov/articles/PMC10115508/
Harden, C., et al. (2017). “Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors.” Neurology, 88(17), 1674–1680. https://www.neurology.org/doi/10.1212/WNL.0000000000003685
Kim-McManus, O.P., et al. (2025). “Antisense oligonucleotide treatment in a preterm infant with early-onset SCN2A developmental and epileptic encephalopathy.” Nature Medicine. https://www.nature.com/articles/s41591-025-03656-0
Kim-McManus, O.P., et al. (2026). “Individualized antisense oligonucleotides for SCN2A-related developmental epileptic encephalopathy.” Nature Medicine. https://www.nature.com/articles/s41591-026-04527-y
CURE Epilepsy. “SUDEP: Sudden Unexpected Death in Epilepsy.” https://www.cureepilepsy.org/understanding-epilepsy/epilepsy-basics/sudep-sudden-unexpected-death-in-epilepsy/
American Epilepsy Society. “The Dragonfly Study: A Longitudinal Natural History Registry of Individuals with SCN2A-Related Disorders.” https://aesnet.org/abstractslisting/the-dragonfly-study-a-longitudinal-natural-history-registry-of-individuals-with-scn2a-related-disorders
SCN2A Foundation. “SCN2A WorldMap.” https://worldmap.scn2afoundation.org/
Heron, S.E., et al. (2002). “Sodium-channel defects in benign familial neonatal-infantile seizures.” The Lancet. https://pubmed.ncbi.nlm.nih.gov/12243921/
Praxis Precision Medicines. (2025). “Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy.” https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-alignment-fda-simplified
Praxis Precision Medicines. (2026). “Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants.” https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-receives-fda-breakthrough-therapy-0
ClinicalTrials.gov. “A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety (EMBRAVE3).” NCT07019922. https://clinicaltrials.gov/study/NCT07019922
Share
If you are reading this, you have probably just typed one of the hardest questions a parent can ask into a search engine. You want to know what an SCN2A diagnosis means for your child’s future — and specifically, how long your child might live. That question deserves an honest answer. Here is the truth: there is no reliable average life expectancy figure specific to SCN2A-related disorders as a whole. But the absence of a single number does not mean the absence of knowledge. Researchers and clinicians understand more about SCN2A outcomes today than at any point in history, and that understanding is growing rapidly.
SCN2A is a gene that provides instructions for making a sodium channel protein critical to brain development and function. Variants in this gene cause a wide spectrum of conditions, from seizures that resolve on their own in infancy, to severe developmental and epileptic encephalopathies (DEEs), which are conditions where developmental impairment arises from both the underlying genetic cause and the effects of epileptic activity itself. Published research describes a broad and overlapping spectrum of clinical presentations associated with SCN2A variants. These include self-limited neonatal or infantile seizures, neurodevelopmental and neuropsychiatric conditions including intellectual disability and autism, infantile epileptic spasms syndrome, early-onset DEEs, and episodic ataxia.
Many individuals show features that span more than one category, and presentations can evolve over time. A computational analysis of more than 10,860 phenotypic annotations across 413 individuals with SCN2A-related disorders underscores just how broad and varied this clinical spectrum is. This range is the core reason why a single life expectancy figure does not exist. A person with a mild, inherited SCN2A variant and a person with a severe, spontaneous (de novo) variant often have very different health trajectories — though variant type alone does not predict outcome.
Grouping all individuals into one statistic would be misleading and potentially harmful. SCN2A was first associated with epilepsy over two decades ago, with initial reports published in 2001–2002. However, the recognition of the full phenotypic spectrum, particularly severe de novo presentations, has expanded significantly only in the past ten to fifteen years. The large, long-term studies needed to generate population-level survival data, studies that track hundreds or thousands of individuals over decades, are only now getting underway. Until those studies mature, we must look at what the existing evidence does tell us.
While no reliable cohort-wide life expectancy figure has been established, published research does describe a range of outcomes based on variant type and clinical presentation.
Some individuals with SCN2A variants experience self-limited neonatal-infantile epilepsy (historically called benign familial neonatal-infantile seizures, or BFNIS) — seizures that typically appear within the first months of life and often resolve spontaneously by early childhood. Many of these individuals go on to have typical development. Inherited SCN2A variants are often associated with milder phenotypes, though this is a pattern rather than a rule. These inherited variants, often gain-of-function (GOF) missense changes passed from a parent, are generally linked to milder presentations. For many families in this group, long-term health expectations are encouraging, but individual outcomes still vary. It is worth noting that “self-limited” does not always mean “no lasting impact.” Some children in this group may still experience learning differences or mild developmental delays. But the overall trajectory for inherited, milder variants tends to be positive, with seizures often resolving and development continuing to progress.
At the more severe end of the spectrum, de novo GOF variants can cause developmental and epileptic encephalopathies (DEEs) such as early infantile DEE (historically called Ohtahara syndrome) or infantile epileptic spasms syndrome (historically called West syndrome). DEE describes conditions where developmental impairment arises from both the underlying genetic cause and the effects of epileptic activity itself. These conditions typically present with seizures within the first three months of life and are associated with significant developmental challenges. Loss-of-function (LOF) variants, where the SCN2A protein has reduced activity, are more often associated with autism spectrum disorder (ASD), intellectual disability, and later-onset or absent seizures. These variants include truncating, splice-site, and some missense changes. Many truncating variants produce little functional protein through a cellular quality-control process called nonsense-mediated decay, rather than producing a stable shortened channel. Outcomes in this group vary widely depending on the degree of developmental involvement and the specific supports available to each individual.
It is important to understand that the genetic change itself does not worsen over time, and SCN2A disorders are not considered neurodegenerative in the way that some progressive neurological conditions are, based on current understanding. However, the clinical picture can evolve as a child grows, seizure types may change, movement difficulties can emerge, and some children may experience developmental stagnation or regression, particularly during periods of frequent seizure activity. This is a meaningful distinction for families trying to understand what the future holds.
Because SCN2A outcomes vary so widely, several factors play a meaningful role in shaping each individual’s long-term health.
For individuals who experience seizures, how well those seizures are managed is one of the most significant factors influencing overall health and quality of life. Frequent generalized tonic-clonic seizures (GTCS), a type involving loss of consciousness and full-body convulsions, are the strongest established risk factor for serious seizure-related complications, including the risk of injury and the risk of sudden unexpected death in epilepsy (SUDEP).
Treatment for SCN2A should be individualized based on each person’s specific variant, clinical presentation, and response to therapy, not on GOF or LOF classification alone. This distinction matters because medications that help one variant type may be ineffective or even harmful for another. Recent research has shown that the mechanisms of SCN2A loss of function do not reliably predict the presence or type of epilepsy, reinforcing the need for personalized treatment strategies. Getting the right treatment early, and avoiding the wrong one, can improve seizure control, which may in turn support development, though developmental outcomes are also shaped by the underlying genetic cause itself. Working with a neurologist experienced in genetic epilepsies, ideally guided by current SCN2A research, is essential. Long-term follow-up is also critical, as the neurological and developmental needs of individuals with SCN2A may shift across different stages of life.
Early intervention services, speech and occupational therapy, behavioral support, and educational accommodations can meaningfully improve quality of life, skill development, and participation for children with developmental differences related to SCN2A. These supports do not change the underlying genetics, but they help each child build skills and reach their fullest potential.
SUDEP — sudden unexpected death in epilepsy — is a concern for all families managing epilepsy, and it deserves transparent discussion. SUDEP is estimated to account for approximately 3,000 deaths annually in the United States across all forms of epilepsy. No reliable population-wide SUDEP rate specific to SCN2A has been established, and it is not possible to directly apply rates from other epilepsy syndromes. However, SUDEP has been reported in individuals with SCN2A-related genetic developmental and epileptic encephalopathies. A 2023 study by Donnan et al. documented rates of SUDEP and status epilepticus across several genetic DEEs, confirming that SCN2A-associated SUDEP does occur — though the cohort was relatively small and the findings should be interpreted with that limitation in mind.
According to the AAN and AES practice guideline on SUDEP, the overall incidence of SUDEP in epilepsy is approximately 1 in 4,500 children per year and 1 in 1,000 adults per year. For individuals experiencing three or more generalized tonic-clonic seizures per year, the risk rises substantially. The strongest established risk factors include frequent generalized tonic-clonic seizures, particularly nocturnal generalized tonic-clonic seizures, and uncontrolled seizure burden. Families should discuss seizure management and optimization strategies, nighttime monitoring options, and seizure action plans with their care team, keeping in mind that no monitoring device has been proven to prevent SUDEP. SUDEP is not the only serious health risk for individuals with severe SCN2A-related disorders.
Status epilepticus, prolonged seizures that do not stop on their own, respiratory infections, aspiration related to feeding and swallowing difficulties, and complications of prolonged immobility can all affect long-term health and survival. These risks are not unique to SCN2A but are important for families managing any severe epilepsy syndrome to discuss with their medical team.
The reason no reliable life expectancy figure has been established for SCN2A is not because the question is unanswerable, it is because the studies needed to answer it are still maturing. Several major initiatives are working to close this gap.
The Dragonfly Study is a longitudinal natural history registry tracking individuals with SCN2A-related disorders over time through the IAMRARE platform. Studies like this one are designed to capture exactly the kind of long-term outcome data that families are searching for. The Simons Searchlight SCN2A research program is another important initiative collecting genetic, medical, and behavioral data from families to deepen scientific understanding of the condition.
The SCN2A WorldMap, a privacy-first global registry built by the SCN2A Foundation, serves a different but complementary role. It creates a consented, geolocated cohort that makes the SCN2A community visible to pharmaceutical companies, regulators, and research funders, and connects families who share identical variants across the globe. The WorldMap supports cohort visibility and the therapeutic-development pipeline, while initiatives like the Dragonfly Study and Simons Searchlight are the programs designed to collect the longitudinal clinical data that will directly inform questions about long-term prognosis.
Active research into gene therapy, antisense oligonucleotide (ASO) therapies, treatments that target the genetic instructions themselves, and mutation-specific drug development is advancing steadily. These approaches aim not just to manage symptoms but to address the root cause of SCN2A-related disorders. One SCN2A ASO therapy, Elsunersen, is currently in a Phase 3 clinical trial (EMBRAVE3, NCT07019922) for early-onset SCN2A-related DEE. The trial was initially designed as a randomized, double-blind, sham-controlled study but was subsequently converted, with FDA agreement, to a single-arm, baseline-controlled design in which all enrolled patients receive elsunersen for 24 weeks, followed by a treatment extension.
Separately, in June 2026, Elsunersen received FDA Breakthrough Therapy Designation, specifically for the treatment of seizures associated with SCN2A-DEE caused by gain-of-function variants, which provides expedited development and more intensive FDA guidance for drugs that treat serious conditions with preliminary evidence of substantial improvement over existing therapies. This designation does not currently extend to loss-of-function variants. Kim-McManus et al. have also published individualized ASO treatments for SCN2A-related DEE in Nature Medicine, first reporting on a preterm infant in 2025, and then on two patients ages 9 and 14 in 2026, landmark examples of precision medicine tailored to each patient’s specific variant.
While no gene-modifying therapy is currently approved for clinical use, the pipeline is active and growing. The pace of discovery in genetic epilepsy has accelerated dramatically in recent years, and SCN2A is increasingly recognized as a priority target. Every new study, every family enrolled in a registry, and every dollar invested in precision medicine brings the field closer to therapies that could fundamentally change the outlook for individuals living with SCN2A-related disorders.
While the research community works toward better data and new therapies, families can take meaningful action right now: Build your care team. Connect with a neurologist and geneticist experienced in SCN2A and sodium channel disorders. Know your child’s variant type, if known. Understanding whether your child’s variant is GOF, LOF, or mixed function — when this information is available — helps guide treatment decisions. Not all variants have been functionally characterized, and your geneticist or neurologist can help clarify what is known about your child’s specific variant. Participate in research. Enrolling in the Dragonfly Study or Simons Searchlight contributes to the longitudinal clinical data that will inform long-term outcome questions. Registering on the SCN2A WorldMap helps make the community visible to researchers and industry. You can join families and researchers working to accelerate this progress. Discuss SUDEP risk. Talk with your child’s care team about seizure optimization strategies, nighttime monitoring options, and seizure action plans. Pursue early intervention. Developmental therapies and educational support make a real difference in quality of life and skill development.
Every family navigating an SCN2A diagnosis deserves answers, community, and hope. The work to find them depends on your support. Please consider making a donation to help fund the research and resources that move us all forward.
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
SCN2A Foundation. “Understanding an SCN2A Prognosis: What Families Need to Know.” https://www.scn2afoundation.org/post/understanding-an-scn2a-prognosis-what-families-need-to-know
Wolff, M., et al. (2017). “Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders.” Brain, 140(5), 1316–1336. https://academic.oup.com/brain/article/140/5/1316/3098477
Wolff, M., Brunklaus, A., & Zuberi, S.M. (2019). “Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond.” Epilepsia. https://onlinelibrary.wiley.com/doi/abs/10.1111/epi.14935
Berg, A.T., et al. (2024). “Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders.” Brain, 147(8), 2761. https://academic.oup.com/brain/article/147/8/2761/7656659
Goad, B.S., et al. (2025). “Development and Adaptive Function in Individuals With SCN2A-Related Disorders.” Neurology, 105(3). https://www.neurology.org/doi/10.1212/WNL.0000000000213868
Tan, M., et al. (2026). “Mechanisms of SCN2A loss of function do not predict presence or phenotype of epilepsy.” Epilepsia. https://onlinelibrary.wiley.com/doi/10.1002/epi.70100
Crawford, K., et al. (2021). “Computational Analysis of 10,860 Phenotypic Annotations in Individuals with SCN2A-Related Disorders.” Genetics in Medicine, 23(10), 1940–1950. https://www.nature.com/articles/s41436-021-01120-1
Donnan, A.M., et al. (2023). “Rates of Status Epilepticus and Sudden Unexplained Death in Epilepsy in People With Genetic Developmental and Epileptic Encephalopathies.” Neurology. https://pmc.ncbi.nlm.nih.gov/articles/PMC10115508/
Harden, C., et al. (2017). “Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors.” Neurology, 88(17), 1674–1680. https://www.neurology.org/doi/10.1212/WNL.0000000000003685
Kim-McManus, O.P., et al. (2025). “Antisense oligonucleotide treatment in a preterm infant with early-onset SCN2A developmental and epileptic encephalopathy.” Nature Medicine. https://www.nature.com/articles/s41591-025-03656-0
Kim-McManus, O.P., et al. (2026). “Individualized antisense oligonucleotides for SCN2A-related developmental epileptic encephalopathy.” Nature Medicine. https://www.nature.com/articles/s41591-026-04527-y
CURE Epilepsy. “SUDEP: Sudden Unexpected Death in Epilepsy.” https://www.cureepilepsy.org/understanding-epilepsy/epilepsy-basics/sudep-sudden-unexpected-death-in-epilepsy/
American Epilepsy Society. “The Dragonfly Study: A Longitudinal Natural History Registry of Individuals with SCN2A-Related Disorders.” https://aesnet.org/abstractslisting/the-dragonfly-study-a-longitudinal-natural-history-registry-of-individuals-with-scn2a-related-disorders
SCN2A Foundation. “SCN2A WorldMap.” https://worldmap.scn2afoundation.org/
Heron, S.E., et al. (2002). “Sodium-channel defects in benign familial neonatal-infantile seizures.” The Lancet. https://pubmed.ncbi.nlm.nih.gov/12243921/
Praxis Precision Medicines. (2025). “Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy.” https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-alignment-fda-simplified
Praxis Precision Medicines. (2026). “Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants.” https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-receives-fda-breakthrough-therapy-0
ClinicalTrials.gov. “A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety (EMBRAVE3).” NCT07019922. https://clinicaltrials.gov/study/NCT07019922
Vlad Magdalin
Accelerating research and treatment for SCN2A-related disorders.
Get the latest SCN2A research and community news.